Sophie Barrett

Carboplatin in BRCA1/2-mutated and triple-negative breast cancer BRCAness subgroups: the TNT Trial

Andrew Tutt, Holly Tovey, Maggie C.U. Cheang et al. · Nature Medicine · 2018 · 862 citations · Full text

Tnt Trial, Breast Oncology, Medicine +7

Overall survival in the OlympiA phase III trial of adjuvant olaparib in patients with germline pathogenic variants in BRCA1/2 and high-risk, early breast cancer

Charles E. Geyer, Judy E. Garber, Richard D. Gelber et al. · Annals of Oncology · 2022 · 404 citations · Full text

Breast Oncology, Overall Survival, Medicine +7

Phase I and Pharmacodynamic Trial of the DNA Methyltransferase Inhibitor Decitabine and Carboplatin in Solid Tumors

Kim Appleton, Helen Mackay, Ian Judson et al. · Journal of Clinical Oncology · 2007 · 228 citations · Full text

Phase II trial of paclitaxel by 3-hour infusion as initial and salvage chemotherapy for metastatic breast cancer.

Andrew D. Seidman, Amy Tiersten, Clifford A. Hudis et al. · Journal of Clinical Oncology · 1995 · 204 citations

Abstract S3-01: The TNT trial: A randomized phase III trial of carboplatin (C) compared with docetaxel (D) for patients with metastatic or recurrent locally advanced triple negative or <i>BRCA1/2</i> breast cancer (CRUK/07/012)

Andrew Tutt, Lucy Kilburn, Cheryl Gilett et al. · Cancer Research · 2015 · 164 citations

Tnt Trial, Tumor Biology, Breast Oncology +14